ZYUS Life Sciences Corporation (ZYUS.V)
| Previous close | 0.8200 |
| Open | 0.7900 |
| Bid | 0.7800 x N/A |
| Ask | 0.7900 x N/A |
| Day's range | 0.7900 - 0.7900 |
| 52-week range | 0.7100 - 1.1900 |
| Volume | |
| Avg. volume | 4,188 |
| Market cap | 58.743M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5500 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireZYUS Life Sciences Corporation Announces Closing of Unsecured Loan
SASKATOON, Saskatchewan, September 28, 2024--ZYUS Life Sciences Corporation (the "Company") (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announces that an independent director of the Company (the "Lender") has agreed to advance a CAD$1,000,000 unsecured loan (the "Loan") to the Company with a closing date on or about October 1, 2024 and subject to the Company f
Simply Wall St.ZYUS Life Sciences Insiders Placed Bullish Bets Worth CA$847.3k
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Business WireZYUS Life Sciences Announces Closing of Private Placement
SASKATOON, Saskatchewan, August 27, 2024--ZYUS Life Sciences Corporation (the "Company") (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce the closing of a non-brokered private placement (the "Private Placement") of 3,510,345 units (each a "Unit") at a price of $0.95 per Unit for aggregate gross proceeds of $3.3 million. Each Unit consists of
